Carl Raczkowski, MD
Gastroenterology · Oklahoma City, OKNPI 1851375646
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 377 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 41.0% of the total.
Across 377 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$797
- Takeda Pharmaceuticals U.S.A., Inc.$378
- QOL Medical, LLC$283
- Sanofi$241
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$213
- plus $2K from 27 others
Across 4 payments — averaging $2915.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Covidien LP$12K
What the payments were for
- Food & beverage$6,194100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,206 in reported general payments places this provider in the 55th percentile of 133 gastroenterology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 28 | $7,715 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 62 | $3,894 |
| Pantoprazole Sodium | 292 | $2,780 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 119 | $1,983 |
| Omeprazole | 66 | $1,259 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 80 | $1,253 |
| Sucralfate | 14 | $637 |
| Famotidine | 28 | $521 |
| Budesonide DrBudesonide | 11 | $482 |
| Ondansetron OdtOndansetron | 29 | $469 |
| Promethazine Hcl | 14 | $424 |
| Dicyclomine Hcl | 14 | $190 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $83 |
| Esomeprazole Magnesium | 13 | $44 |
| Prednisone | 12 | $34 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Oklahoma City
- George SalemOklahoma City$1.2M
- Tauseef AliOklahoma City$536K
- Pooja SinghalOklahoma City$140K
- Hussein BitarOklahoma City$120K
- Trushar PatelOklahoma City$49K
- Matthew McBrideOklahoma City$33K
- Sanjay SikkaOklahoma City$31K
- Tony TranOklahoma City$11K
- Ahmad Al-TaeeOklahoma City$11K
- Sumit WaliaOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.